Grünenthal: complaint about frequency/volume of Palexia promotional mailings (AUTH/2513/6/12) – no breach

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2513/6/12
ComplainantAnonymous employee (non-contactable)
CompanyGrünenthal Ltd
MedicinePalexia (tapentadol)
IssueAlleged excessive frequency/volume of promotional mailings (including implication of mailing after every call)
Applicable Code year2012
Clauses considered9.1 and 11.2
DecisionNo breach
Complaint received13 June 2012
Case completed26 June 2012
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable employee complained about the frequency and volume of Palexia (tapentadol) promotional mailings to health professionals.
  • The allegation was that after every call on a target customer, Grünenthal sent a brand reminder mailer and dosage card—potentially resulting in more than eight mailings per year and/or several in a short period.
  • The complainant provided an internal marketing newsletter stating that a call would be picked up in the CRM system and within 7 days a letter and dosage card would be mailed to the customer.
  • The PMCPA asked Grünenthal to respond under Clauses 9.1 and 11.2.
  • Grünenthal said the contact-activated brand reminder mailing was designed to be sent only once per GP during its active period (April–December 2012), with duplication prevented via mailing-provider checks against prior recipients.
  • Grünenthal provided mailing history and planning controls, stating that from February 2011 to June 2012 the maximum any single GP could have received was four Palexia mailings; any single secondary care health professional two.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 11.2 (restraint on frequency/volume of promotional material).
  • No breach of Clause 9.1 (high standards).
  • The Panel noted the newsletter could have been more clearly stated because it implied a mailing after every call, but the evidence supported Grünenthal’s process and volumes.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training